This episode of This Week in Microbiology (TWiM 332) explores two distinct yet fascinating areas of microbial science. The first segment delves into a comprehensive study of the International Space Station's (ISS) unique microbial and chemical environment. This "built environment" is shown to be dominated by human-associated microbes (primarily Staphylococcus), influenced by crew and module use patterns, and characterized by synthetic chemicals from cleaning and personal care products. Notably, a high prevalence of antimicrobial resistance (AMR) genes is found, indicating selective pressures unique to space. The study highlights the potential health implications for astronauts, including immune dysfunction and recurrent viral infections, and suggests that introducing beneficial microbes or modifying sanitation could improve astronaut health.
The second part of the episode focuses on groundbreaking research connecting the gut microbiome to fibromyalgia pain. A study in Neuron demonstrates that transplanting gut microbiota from fibromyalgia patients into germ-free mice induces pain and other associated phenotypes like immune activation and reduced skin innervation. The discussion emphasizes that the mechanism involves soluble mediators and dysregulated bile acid metabolism, rather than direct gut barrier dysfunction or inflammation. A small, open-label human pilot trial further supports these findings, showing that healthy fecal microbiota transplantation (FMT) significantly reduced pain and improved quality of life in fibromyalgia patients, offering a promising, novel therapeutic avenue for this often-misunderstood chronic condition.
Summarizing TWiM 332: Fibromyalgia Pain and the Gut Microbiome
0:00 Introduction to TWiM: The podcast, supported by Microbe.tv and the American Society for Microbiology, introduces hosts Vincent Racaniello, Michelle Swanson, and Michael Schmidt, emphasizing their commitment to real science over misinformation.
1:57 International Space Station (ISS) Environment Study: A study published in Cell investigates the unique and extreme microbial and chemical environment of the ISS, a "built environment" isolated from Earth.
6:05 Relevance to Earth & Astronaut Health: The ISS environment is compared to hospitals due to shared characteristics like controlled atmospheres and plastic surfaces. Astronauts on the ISS experience ailments like rashes, allergies, immune dysfunction (including herpes virus reactivation), and infections, highlighting the need to understand this environment.
8:36 Human-Dominated Microbes: Sampling of 803 surface samples on the US orbital segment revealed that human skin is the primary source of microbes on the ISS, with minimal contributions from terrestrial sources. The most abundant microbe found was Staphylococcus.
11:10 Chemical Hotspots & Sources: Mass spectrometry identified chemicals on ISS surfaces, many originating from microbial sources, food, human excretions (e.g., urinary metabolites in the toilet module), and personal care products. Disinfection activities also leave chemical residues and influence microbial life.
16:50 ISS as an Extreme Environment: The ISS is characterized as the most extreme built environment due to its isolation. While Staphylococcus dominates both the ISS and Earth's built environments, the ISS shows reduced numbers of other common bacteria.
21:33 High Antimicrobial Resistance (AMR) Genes: The study found 1,650 AMR genes from 22 different classes, present in over 90% of surface samples. This high prevalence is attributed to the selective pressure from harsh chemicals and potential oxidative stress in space, distinguishing it from average homes on Earth.
24:19 Viruses and Microbial Adaptation: Human-origin viruses (polyoma, papilloma, herpes viruses) are found, with frequent herpes virus reactivation due to stress. There is evidence of bacterial adaptation to the space environment, with distinct clustering of AMR genes in one bacterium, Pantonoea ananatis, which was likely brought via fresh produce.
27:19 Probiotic Sanitation & Future Directions: The study suggests considering probiotic-based sanitation measures to align the ISS's microbial communities more with Earth's environmentally exposed habitats and minimize cross-contamination between modules.
28:20 Fibromyalgia Pain and the Gut Microbiome Study: A Neuron paper presents research on the connection between the gut microbiome and fibromyalgia, a mysterious chronic widespread pain condition affecting up to 4% of the global population.
30:04 Transplanting Fibromyalgia Microbiota Induces Pain in Mice: Transplanting gut microbiota from women with fibromyalgia into germ-free or gnotobiotic mice induces pain and other common patient phenotypes, such as immune activation, metabolomic changes, and reduced skin innervation.
36:50 Quantitative Pain Assessment in Mice: The researchers used various quantitative behavioral studies (e.g., von Frey test, radiant heat paw withdrawal, cold paw, grimace scale) to demonstrate pain in mice, ensuring objective measurement.
43:08 Immune and Metabolic Alterations: Mice receiving fibromyalgia microbiota showed increased classical monocytes, enrichment of inflammatory cytokines (IL-17, TNF), and altered metabolic profiles, with effects developing over weeks rather than hours.
45:00 Mechanisms Beyond Gut Barrier Dysfunction: The study suggests that pain is not due to direct gut barrier damage but rather soluble mediators made in the gut that travel to other organs. Dysregulation of bile acid metabolism, specifically reduced levels of certain bile acids, is identified as a fundamental trigger for pain.
52:00 Human Pilot Clinical Trial: An open-label pilot trial with 14 women suffering from severe, refractory fibromyalgia involved fecal microbiota transplantation (via "poop pills") from healthy donors.
56:15 Significant Pain Reduction & Improved Quality of Life: One week after the transplant, 12 of 14 patients experienced a clinically and statistically significant decrease in pain intensity (greater than two points on a 10-point scale), along with improved anxiety, depression, sleep quality, and physical quality of life scores.
57:50 Future Research & Hope for Patients: While the effects were not stable long-term, the promising pilot results warrant a larger controlled clinical trial. The research offers a guiding light for developing effective treatments for fibromyalgia, a disease whose symptoms have often been disregarded by the medical system.
59:26 Postdoctoral Researcher's Perspective: Dr. Waya Kai, the first author, shares her journey and the profound fulfillment of working on research with real-world impact, emphasizing the importance of team science and collaboration in tackling complex problems.